Armata pharmaceuticals, inc. (APHB)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue

-

-

-

-

-

-

-

-

-

115

117

108

183

260

366

480

479

475

450

408

0

-

0

0

-

-

-

-

0

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

163

81

0

0

0

Operating expenses
Research and development (benefit)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

2,855

2,881

0

0

0

-

-

5,164

5,000

3,992

3,890

4,955

5,766

5,805

5,802

5,132

6,839

6,469

0

0

0

Research and development

0

-

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development benefit

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

10,056

9,265

7,077

3,833

2,308

2,519

3,957

5,056

7,283

7,590

7,832

8,000

7,667

8,413

8,729

8,791

7,957

6,710

6,418

6,276

6,620

6,850

6,513

6,027

6,909

5,996

0

0

0

Impairment charges

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Severance expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

Total operating expenses

-

-

24,872

20,524

-

17,658

10,712

9,067

15,938

16,271

25,772

28,424

22,402

23,638

14,820

13,955

12,957

10,702

10,332

13,095

14,250

14,519

14,155

11,159

13,748

12,465

0

0

0

Loss from operations

-21,232

-19,752

-24,707

-20,359

-18,044

-17,658

-10,692

-9,009

-15,852

-16,156

-25,655

-28,316

-22,219

-23,378

-14,454

-13,475

-12,478

-10,227

-9,884

-12,687

-13,843

-14,110

-14,099

-11,209

-13,585

-12,384

0

0

0

Other income (expense)
Interest income

50

96

159

204

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of Preferred B stock derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

-

-

-

-

-

Other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

-

302

0

0

0

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Amortization of note discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Amortization of note discount and patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Interest expense

753

900

1,033

1,124

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

233

0

0

0

Other income (expense)

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense)

-

-

-

0

-

-

-

-

-

-

0

0

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liabilities

-

1,117

3,126

3,021

1,763

1,724

-272

-204

1,817

2,010

4,132

5,201

3,246

4,538

-4,066

2,640

16,036

9,940

22,154

21,495

13,538

9,455

6,730

-46,729

-58,190

-49,330

0

0

0

Total other income (expense), net

414

273

2,184

2,020

737

956

-732

-423

1,824

2,016

3,811

4,876

2,691

3,984

2,812

9,647

23,270

9,638

10,935

29,506

33,766

37,219

38,330

-34,520

-60,660

-52,199

0

0

0

Loss before income taxes

-

-

0

0

-

-

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-20,818

-19,479

-22,523

-18,339

-17,307

-16,702

-11,424

-9,432

-12,726

-12,838

-19,986

-21,582

-18,972

-18,838

-11,569

-3,755

10,865

-516

1,051

16,819

19,923

23,109

24,231

-45,729

-74,245

-64,583

0

0

0

Unrealized gain on investments

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Excess of fair value of consideration transferred on conversion of Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

1,858

2,807

9,970

11,665

10,278

9,659

2,819

1,309

1,285

1,184

1,147

932

618

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-22,685

-24,276

-17,956

-16,091

-800

-10,794

-14,675

7,933

12,547

15,757

23,047

-46,876

-75,177

-65,201

0

0

0

Per share information:
Net loss per share, basic and diluted (in dollars per share)

-0.49

-

-

-

-0.80

-

-

-

-0.24

-

-

-

-1.94

-

-

-

-8.22

-

-

-

-

-

-

-

-0.06

-

-

-

-0.03

Weighted average shares outstanding, basic and diluted

10,451

-

-

-

4,652

-

-

-

13,298

-

-

-

1,677

-

-

-

588

-

-

-

-

-

-

-

182,535

-

-

-

66,908

Net loss

-20,818

-19,479

-22,523

-18,339

-17,307

-16,702

-11,424

-9,432

-12,726

-12,838

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basic

-

-

-0.73

-0.56

-

-

-0.60

-0.68

-

-

-0.09

-1.21

-

-

-3.23

-7.26

-

-

-0.30

1.27

-3.49

-

5.58

3.69

-

-

-0.49

-0.16

-

Weighted average shares outstanding, basic

-

-

9,552

7,505

-

-

4,652

4,652

-

-

8,874

5,350

-

-

1,112

874

-

-

5,813

5,667

4,245

-

3,743

3,671

-

-

99,156

90,645

-

Net loss per share, diluted

-

-

-0.73

-0.69

-

-

-0.60

-0.68

-

-

-0.09

-1.46

-

-

-3.23

-7.82

-

-

-0.30

-0.33

-3.49

-

3.30

2.09

-

-

-0.49

-0.16

-

Weighted average shares outstanding, diluted

-

-

9,552

7,720

-

-

4,652

4,652

-

-

8,874

5,519

-

-

1,112

876

-

-

5,813

7,545

4,245

-

6,319

6,497

-

-

99,156

90,645

-